Avalyn Pharma (NASDAQ:AVLN) Shares Down 5.1% – What’s Next?

Posted by Brenda Bartman on Oct 7th, 2026

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) fell 5.1% on Monday. The stock traded as low as $26.69 and last traded at $26.69. Approximately 91,164 shares changed hands during trading, a decline of 71% from the average daily volume of 313,573 shares. The stock had previously closed at $28.13.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AVLN. Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Morgan Stanley upped their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They set a “sell (d+)” rating on the stock. Finally, Raymond James Financial started coverage on shares of Avalyn Pharma in a research note on Friday. They issued an “outperform” rating and a $60.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

View Our Latest Analysis on Avalyn Pharma

Avalyn Pharma Price Performance

The business has a 50-day moving average of $33.44. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The company has a market capitalization of $1.13 billion and a price-to-earnings ratio of -1.11.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.05. On average, equities analysts expect that Avalyn Pharma Inc. will post -3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp bought a new stake in Avalyn Pharma during the second quarter worth about $10,501,000. Braidwell LP bought a new position in Avalyn Pharma in the 2nd quarter valued at about $26,382,000. Montanova Capital LLC acquired a new position in shares of Avalyn Pharma in the 2nd quarter valued at approximately $82,402,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma in the 2nd quarter valued at approximately $1,321,000.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.